Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Isis Stories

2013-11-14 08:38:34

MILLIONS OF AT&T CUSTOMERS NATIONWIDE CAN NOW TAP TO PAY USING THE ISIS MOBILE WALLET® DALLAS, Nov. 14, 2013 /PRNewswire/ -- Starting today, AT&T customers nationwide can use their smartphone as a wallet when they download the Isis Mobile Wallet® from Google Play. Currently, AT&T's portfolio of smartphones includes 19 different Android models that support Near Field Communication (NFC) and are capable of using the Isis Mobile Wallet(TM). Isis, which announced nationwide...

2013-11-14 08:30:00

Updated App Delivers Simple, Elegant User Experience; Showcased at Thousands of Wireless Carrier Retail Stores NEW YORK, Nov. 14, 2013 /PRNewswire/ -- Isis®, the mobile commerce joint venture created by AT&T Mobility, T-Mobile USA, Inc. and Verizon Wireless, today announced the latest version of the Isis Mobile Wallet® is now available to consumers for download in the Google Play app store and at thousands of AT&T, T-Mobile and Verizon Wireless retail stores nationwide. The Isis...

2013-11-13 12:22:33

Insightful new inspirational book "Practical Grace: Through the Eyes of a Believer" offers step-by-step strategy for becoming a "Masterful" Christian by shifting one's mindset and relinquishing judgment MIAMI, Nov. 13, 2013 /PRNewswire/ -- In an effort to convey the gift of grace to other believers this Christmas, Isis Perez-Gonzalez (www.isispg.com) has authored an insightful, no-nonsense guide that shares skills and strategies to activate grace from a personal perspective, not a...

2013-11-12 08:34:13

CARLSBAD, Calif., Nov. 12, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from Biogen Idec related to the advancement of the ongoing Phase 2 study of ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA). (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) The Phase 2 study of ISIS-SMN(Rx) is an open-label, multiple-dose, dose-escalation pilot study in infants who have been diagnosed...

2013-11-05 08:35:12

-Improved 2013 financial guidance CARLSBAD, Calif., Nov. 5, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $22.7 million and $23.5 million for the three and nine months ended September 30, 2013, respectively, compared to a pro forma NOL of $26.0 million and $36.0 million for the same periods in 2012. On a GAAP basis, Isis reported a loss from operations of $25.5 million and $31.8 million for the three and nine months...

2013-11-04 23:26:24

d-Wise Technologies also announces the availability of SOA’s Semantic Manager metadata repository as the initial system and an integral component of their Integrated Services and Integrated Systems solution, ISIS Clinical, and a New Clinical Data Standards Delivery Model that bundles strategy, implementation and conversion services for CDISC. Morrisville, NC (PRWEB) November 04, 2013 d-Wise, a leading life science and healthcare technology consulting and solution provider, announced...

2013-10-29 08:31:28

CARLSBAD, Calif., Oct. 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Third Quarter 2013 Financial Results and Highlights Conference Call When: Tuesday, November 5, 2013 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How:...

2013-10-24 08:31:55

Mobile NFC a Blip in the Multi-Trillion Dollar Global Retail Sector BOSTON, Oct. 24, 2013 /PRNewswire/ -- Strategy Analytics has lowered its outlook for NFC-based mobile payments to reflect the slow pace at which operators are pushing NFC payment services, limited NFC payment deployments by handset makers, and the continued slow adoption of contactless payments by retailers. The Strategy Analytics Wireless Media Strategies (WMS)service report "NFC Mobile Payments Forecast Update:...

2013-10-16 08:26:49

CARLSBAD, Calif., Oct. 16, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the selection and advancement of ISIS-DMPK(Rx) to treat myotonic dystrophy type I (DM1). (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) "We are very pleased with the successes we are having in our alliance with Biogen Idec. The progress we have made is evidenced in our spinal...

2013-10-09 16:21:21

CARLSBAD, Calif., Oct. 9, 2013 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2013 Distinguished Scientist Award by the San Diego section of the American Chemical Society (ACS). The award recognizes Dr. Crooke's contributions in leading Isis Pharmaceuticals, a long-standing leader in drug discovery in the San Diego community. Isis' innovative RNA-based drug...